1. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the swiss group for clinical cancer research SAKK
- Author
-
W. Mingrone, D. Helbling, R. von Moos, Arnaud Roth, Clemens B. Caspar, Thomas Ruhstaller, B. Pestalozzi, Dieter Rauch, Andreas Trojan, Viviane Hess, Markus Borner, Doris Lanz, D. Koeberle, A. Kappeler, Piercarlo Saletti, Daniel Dietrich, University of Zurich, and Borner, M
- Subjects
Oncology ,Male ,Time Factors ,Organoplatinum Compounds ,Colorectal cancer ,2720 Hematology ,Phases of clinical research ,Cetuximab ,law.invention ,Randomized controlled trial ,law ,Antineoplastic Combined Chemotherapy Protocols ,Neoplasm Metastasis ,ddc:616 ,Aged, 80 and over ,Antibodies, Monoclonal ,Hematology ,Middle Aged ,Oxaliplatin ,Treatment Outcome ,Tolerability ,2730 Oncology ,Female ,Colorectal Neoplasms ,Exanthema/chemically induced ,Organoplatinum Compounds/administration & dosage/adverse effects ,Switzerland ,medicine.drug ,medicine.medical_specialty ,610 Medicine & health ,Antineoplastic Agents ,Antibodies, Monoclonal, Humanized ,Drug Administration Schedule ,Capecitabine ,Internal medicine ,medicine ,Humans ,Colorectal Neoplasms/drug therapy/pathology/radiography ,neoplasms ,Aged ,Antibodies, Monoclonal/administration & dosage/adverse effects ,Performance status ,business.industry ,Neoplasm Metastasis/drug therapy/pathology/radiography ,Exanthema ,medicine.disease ,digestive system diseases ,Surgery ,Radiography ,10032 Clinic for Oncology and Hematology ,Antineoplastic Agents/administration & dosage/adverse effects ,Antineoplastic Combined Chemotherapy Protocols/therapeutic use ,business ,Follow-Up Studies - Abstract
BACKGROUND: To determine the activity and tolerability of adding cetuximab to the oxaliplatin and capecitabine (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC). PATIENTS AND METHODS: In a multicenter two-arm phase II trial, patients were randomized to receive oxaliplatin 130 mg/m(2) on day 1 and capecitabine 1000 mg/m(2) twice daily on days 1-14 every 3 weeks alone or in combination with standard dose cetuximab. Treatment was limited to a maximum of six cycles. RESULTS: Seventy-four patients with good performance status entered the trial. Objective partial response rates after external review and radiological confirmation were 14% and 41% in the XELOX and in the XELOX + Cetuximab arm, respectively. Stable disease has been observed in 62% and 35% of the patients, with 76% disease control in both arms. Cetuximab led to skin rash in 65% of the patients. The median overall survival was 16.5 months for arm A and 20.5 months for arm B. The median time to progression was 5.8 months for arm A and 7.2 months for arm B. CONCLUSION: Differences in response rates between the treatment arms indicate that cetuximab may improve outcome with XELOX. The correct place of the cetuximab, oxaliplatin and fluoropyrimidine combinations in first-line treatment of MCC has to be assessed in phase III trials.
- Published
- 2008
- Full Text
- View/download PDF